Identifizierung spezifischer tumoraffiner Peptide für HNO-Malignomen mittels Display-Techniken

• Antragstellerinnen / Antragsteller: Professor Dr. Uwe Haberkorn; Professorin Dr. Christel Herold-Mende
• Fachliche Zuordnung: Pharmazie ; Nuklearmedizin, Strahlentherapie, Strahlenbiologie
• Förderung: Förderung von 2014 bis 2018
• Projektkennung: Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 256151267

• Erstellungsjahr: 2018

Zusammenfassung der Projektergebnisse

In conclusion, we successfully identified a novel stable av06 integrin-specific peptide with high affinity for a variety of HNSCC tumors and further carcinomas. We observed a strong accumulation of the SFTIGv6 peptide in different tumors, but not in inflammatory lesions and tumor-free healthy tissues of patients. Therefore, SFITGv6 represents a promising tracer for imaging and possibly therapy of several carcinomas expressing the av06 integrin. However, the theranostic application of SFITGv6 to avb6 integrin-positive tumor lesions below the diaphragm (e.g. pancreatic and ovarian cancer) requires the modulation and improvement of the pharmacokinetic properties of the peptide.

Projektbezogene Publikationen (Auswahl)

• Identification of a Novel ITGavß6-Binding Peptide Using Protein Separation and Phage Display. Clin Cancer Res. 2017 Aug 1;23(15):4170-4180
  Altmann A, Sauter M, Roesch S, Mier W, Warta R, Debus J, Dyckhoff G, Herold-Mende C, Haberkorn U
  (Siehe online unter https://doi.org/10.1158/1078-0432.CCR-16-3217)
• Comparative study of the novel RGD Motif-containing avß6 Integrin Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC. J Nucl Med. 2018 Apr 19
  Roesch S, Lindner T, Sauter M, Loktev A, Flechsig P, Müller M, Mier W, Warta R, Dyckhoff G, Herold-Mende C, Haberkorn U, Altmann A
  (Siehe online unter https://doi.org/10.2967/jnumed.118.210013)